[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microcirculatory-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microcirculatory-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,94,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100641345","papaverine-and-sublingual-microcirculation-in-septic-shock-100641345",false,"NCT07657741","Papaverine and Sublingual Microcirculation in Septic Shock","Effects of Papaverine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective, Multicenter, Single-arm, Open-label, Pilot Physiological Study","Inclusion Criteria:\n\n* Age 18-85 years.\n* Septic shock according to Sepsis-3 criteria, defined as suspected or documented infection requiring vasopressors to maintain mean arterial pressure ≥65 mmHg and serum lactate \\>2 mmol\u002FL after adequate fluid resuscitation.\n* Enrollment within 24 hours after diagnosis of septic shock in the ICU.\n* Receiving continuous norepinephrine infusion at enrollment.\n* Receiving invasive mechanical ventilation at enrollment, allowing assessment of vascular waterfall-related hemodynamic variables.\n* PiCCO-based hemodynamic monitoring, invasive arterial pressure monitoring, and central venous access available before papaverine administration.\n* Ability to obtain sublingual microcirculatory images of acceptable quality at baseline.\n* Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Shock primarily caused by non-septic etiologies, including cardiogenic, hypovolemic, obstructive, hemorrhagic, or anaphylactic shock.\n* Expected death or planned withdrawal of life-sustaining treatment within 24 hours.\n* Known allergy or hypersensitivity to papaverine.\n* Severe hemodynamic instability judged unsuitable for papaverine by the treating physician, including refractory hypotension or rapidly escalating vasopressor requirement.\n* Clinically significant arrhythmia, high-grade atrioventricular block, acute coronary syndrome, or active myocardial ischemia before enrollment.\n* Severe hepatic dysfunction judged by the investigator to substantially increase the risk of papaverine-related adverse effects.\n* Conditions preventing reliable sublingual microcirculatory assessment, including major oral or sublingual lesions, active oral bleeding, inability to access the sublingual area, or poor baseline image quality.\n* Pregnancy or lactation.\n* Participation in another interventional clinical trial that may affect study outcomes or safety.","ALL","18 Years","85 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, multicenter, single-arm, open-label, pilot physiological study designed to evaluate the effects of intravenous papaverine on sublingual microcirculation and the vascular waterfall phenomenon in adult patients with septic shock.\n\nEligible patients will have septic shock according to Sepsis-3 criteria, require norepinephrine support after adequate fluid resuscitation, and have PiCCO-based hemodynamic monitoring available before papaverine administration. Papaverine will be administered as an intravenous infusion of 30 mg over 10 minutes, followed by a continuous infusion of 2-5 mg\u002Fhour. Sublingual microcirculatory variables, vascular-waterfall-related indices, PiCCO-derived hemodynamic variables, macrocirculatory parameters, tissue perfusion variables, vasopressor dose, and safety outcomes will be assessed before and after papaverine administration.\n\nThe study aims to explore whether papaverine can improve microvascular perfusion and reduce microcirculatory flow impairment in septic shock, and to provide preliminary physiological and safety data for future controlled trials.",[27,28,29,30],"Septic Shock","Microcirculatory Dysfunction","Sublingual Microcirculation","Hemodynamic Instability",[32,33,34,35,36,37,38,39,40,41],"Septic shock","Papaverine","Sublingual microcirculation","Microcirculatory dysfunction","Vascular waterfall phenomenon","Critical closing pressure","Perfused vessel density","Microvascular flow index","Proportion of perfused vessels","Pilot physiological study","NOT_YET_RECRUITING","2026-06-14",{"date":45,"type":46},"2026-06-18","ACTUAL",{"date":48,"type":21},"2026-08-01",{"date":50,"type":21},"2027-12-30",{"name":52,"class":53},"First Affiliated Hospital of Wannan Medical College","OTHER",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100631250","coronoary-microcirculation-analysis-network-100631250","NCT07498231","COronoary Microcirculation Analysis NETwork","Assessment of Risk Factors for Coronary Circulatory and Microcirculatory Disorders, Comparison of Invasive and Non-Invasive Diagnostic Methods, and Evaluation of the Impact of Individualized Pharmacotherapy Optimization on Patients' Quality of Life","COMA-NET","Inclusion Criteria:\n\na. Chronic coronary syndrome c. Anginal symptoms \\> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Angiographically significant coronary artery stenosis or FFR \\\u003C 0.8\n2. Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n3. Left ventricular ejection fraction \\\u003C 40%\n4. Hypertrophic cardiomyopathy\n5. Acute coronary syndrome within \\\u003C 90 days\n6. Percutaneous coronary intervention (PCI) within \\\u003C 90 days\n7. Previous coronary artery bypass grafting (CABG)\n8. Anemia \\\u003C 10 g\u002FdL or thrombocytopenia \\\u003C 100,000\u002FµL\n9. Intraventricular conduction disturbances preventing ST-T segment assessment\n10. Severe concomitant valvular heart disease\n11. Active malignancy\n12. Type 1 diabetes mellitus\n13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \\> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)\n14. Pregnancy\n15. Heart failure ≥ NYHA class III\n16. Asthma or COPD with severe irreversible airflow obstruction\n17. Atrial fibrillation\n18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)\n19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway","75 Years",{"count":65,"type":21},180,[24],"COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.\n\nPharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.\n\nParticipants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).\n\nThe study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.",[69,70,71,28,72,73,74],"Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Status","Echocardiography","Doppler Echocardiography",[76,77,78,79,80,81,82],"coma.net","coma-net","coronary microcirculation","ANOCA","INOCA","angina with non-obstructive coronary arteries","ischemia with non-obstructive coronary arteries","RECRUITING","2026-04-02",{"date":86,"type":46},"2026-04-08",{"date":88,"type":46},"2025-10-10",{"date":90,"type":21},"2028-03",{"name":92,"class":53},"Medical University of Bialystok",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":110,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100626930","cardiovascular-phenotypes-in-sepsis-100626930","NCT07442032","Cardiovascular Phenotypes in Sepsis","CaPS","Inclusion Criteria:\n\n* Age 18 years or older\n* Suspected sepsis based on clinical evaluation and supporting laboratory findings\n* Hemodynamic instability, defined as mean arterial pressure \\\u003C 65 mmHg despite adequate fluid resuscitation\n* Requirement for vasopressor support\n* Inclusion within 72 hours of admission to an Intermediate Care Unit (IMCU), Intensive Care Unit (ICU), Cardiac Care Unit (CCU), or Acute Care Unit (ACU)\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Advanced peripheral arterial disease, including: subclavian artery occlusion with vertebrobasilar symptoms, critical hand ischemia with tissue loss or non-healing wounds, multilevel occlusive disease affecting upper-extremity arteries, upper limb surgery or significant upper limb trauma within 30 days prior to admission, technical limitations preventing proper placement of the EndoPAT device (e.g., finger amputation, severe rheumatologic deformity, or marked extremity edema).",{"count":102,"type":21},400,"OBSERVATIONAL","This prospective observational study will investigate cardiovascular phenotypes in adults with sepsis and hemodynamic instability. Approximately 400 patients requiring vasopressor support will be enrolled across multiple hospital sites. Within 72 hours of admission, participants will undergo peripheral vascular assessments, echocardiography, and blood sampling for cardiac, endothelial, and inflammatory biomarkers. Patients will be classified according to the presence or absence of peripheral vascular dysfunction and cardiac dysfunction. The primary aim is to examine the association between these cardiovascular phenotypes and one-year mortality. Secondary aims include evaluating biomarker profiles, characterizing myocardial injury, and assessing cardiac function at a 3-month follow-up. The study seeks to improve understanding of sepsis-related cardiovascular dysfunction and support development of more individualized management strategies.",[106,27,107,28,108,109],"Sepsis","Cardiovascular Dysfunction","Troponin Elevation","Peripheral Vascular Response",[106,111,112,113,114,115,116,117],"septic shock","cardiovascular dysfunction","microcirculatory dysfunction","cardiac biomarkers","troponin","peripheral arterial tonometry","echocardiography","2026-02-26",{"date":120,"type":46},"2026-03-02",{"date":122,"type":21},"2026-04-06",{"date":124,"type":21},"2029-12-31",{"name":126,"class":53},"Karolinska Institutet",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":137,"conditions":138,"keywords":145,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":93},"100623641","submental-tissue-oxygenation-and-arterial-lactate-in-major-surgery-100623641","NCT07399275","Submental Tissue Oxygenation and Arterial Lactate in Major Surgery","Relationship Between Submental Tissue Oxygenation, Microvascular Reactivity, and Arterial Lactate During Major Surgical Procedures","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Scheduled for major surgical procedures under general anesthesia\n* Major surgery defined as procedures associated with a risk of significant blood loss and\u002For impaired tissue perfusion, requiring invasive arterial blood pressure monitoring and hourly arterial blood gas analysis\n* Planned intraoperative arterial catheter placement as part of routine clinical care\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Refusal or inability to provide informed consent\n* Absence of invasive arterial blood pressure monitoring\n* Known pregnancy\n* Severe peripheral vascular disease affecting upper extremities\n* Anatomical abnormalities or skin conditions preventing placement of NIRS sensors on the submental or thenar regions\n* Emergency surgery requiring immediate intervention\n* Preoperative severe metabolic acidosis (arterial pH \\\u003C 7.20)",true,{"count":136,"type":21},150,"During major surgical procedures performed under general anesthesia, changes in blood flow and oxygen delivery to tissues may occur due to blood loss, hemodynamic fluctuations, and anesthesia-related physiological effects. These changes can lead to impaired tissue perfusion, which is commonly reflected by increased arterial lactate levels. However, lactate measurements are intermittent and may not detect early perfusion abnormalities.\n\nThis prospective observational study aims to investigate the relationship between submental tissue oxygenation measured by near-infrared spectroscopy (NIRS), microvascular reactivity assessed by the vascular occlusion test, and arterial lactate levels during major surgery. Adult patients undergoing major abdominal, neurosurgical, or orthopedic procedures will be monitored intraoperatively using non-invasive NIRS techniques, while arterial blood gas analyses will be performed as part of routine clinical care.\n\nThe study does not involve any changes to standard anesthesia or surgical management. All treatments and clinical decisions will be made by the responsible care team according to routine practice. By evaluating non-invasive indicators of tissue oxygenation and microvascular function, this study aims to improve the understanding of early intraoperative tissue perfusion changes and their association with metabolic markers.",[28,139,72,140,141,142,143,144],"Tissue Hypoperfusion","Microvascular Circulation","Near Infrared Spectroscopy","Vascular Occlusion Test","Lactate Blood Increase","Major Surgery",[146,147,148,149,150,151],"tissue hypoperfusion","microvascular circulation","Near infrared spectroscopy","vascular occlusion","lactate blood increase","Major surgery","2026-02-03",{"date":154,"type":46},"2026-02-10",{"date":156,"type":21},"2026-02-15",{"date":158,"type":21},"2027-02-15",{"name":160,"class":161},"Bursa Sevket Yilmaz Training and Research Hospital","OTHER_GOV"]